The present invention belongs to the field of disease treatment, and relates to the use of a recombinant anti-IL-23p19 antibody in the treatment of moderate and severe psoriasis, and a method for treating moderate and severe psoriasis in subjects, comprising administering an effective amount of the anti-IL-23p19 antibody to a subject.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Provided is an antibody engineered with a reactive cysteine residue, and more specifically, provided is an antibody having therapeutic or diagnostic application. Also provided is an immunoconjugate comprising the engineered antibody. Further provided are a drug or pharmaceutical composition comprising the antibody or antibody-drug conjugate, and a method and use for applying the antibody or immunoconjugate to treatment of diseases such as tumors.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present invention relates to a trispecific antigen-binding protein, and more specifically to a trispecific antibody specifically binding to two tumor antigens of GPRC5D and BCMA and T cell surface antigen CD3, and a pharmaceutical composition comprising same, a preparation method and the use.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
METHOD FOR TREATING PLAQUE PSORIASIS WHEREIN SUBJECT PREVIOUSLY RECEIVING BIOLOGIC THERAPY FOR PLAQUE PSORIASIS SWITCHES TO USING ANTI-IL23P19 ANTIBODY
A method for treating a plaque psoriasis subject previously receiving biologic therapy for plaque psoriasis, comprising: administering an effective amount of an anti-IL-23p19-subunit antibody to the subject. The present invention further relates to use of the anti-IL-23p19 antibody in the treatment of plaque psoriasis subjects previously receiving biologic therapy.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
Disclosed herein are methods of treating neovascular age-related macular degeneration ( "nAMD" ) and diabetic macular edema ( "DME" ) in a subject in need thereof using a fusion protein that inhibits both the VEGF and complement pathways (e.g., efdamrofusp alfa). Disclosed herein include, inter alia, treatment regiments comprising a loading phase and a maintenance phase.
A novel antibody and antibody fragment that specifically bind to OX40L, and a composition containing the antibody or antibody fragment. In addition, also provided are a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, a related use, and a therapeutic and diagnostic use of the antibody and antibody fragment.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are an antibody having an improved affinity for specifically binding to BCMA, an antibody further comprising a P329G mutation, and a conjugate, a fusion, a bispecific antibody or a pharmaceutical composition comprising the antibody. In addition, further provided are a nucleic acid encoding the antibody, a host cell comprising the nucleic acid, and a method for preparing the antibody. The present invention also relates to the therapeutic and diagnostic use of the antibody binding to BCMA.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a method for treating inflammatory bowel diseases by using a recombinant anti-interleukin (IL) 23p19 subunit antibody, comprising ulcerative colitis and Crohn's disease, and in particular to a dosage regimen for preventing or treating mild ulcerative colitis and moderate and severe ulcerative colitis by using the anti-IL-23p19 antibody.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 37/00 - Drugs for immunological or allergic disorders
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
9.
PREPARATION AND USE OF ANTI-GPRC5D/BCMA/CD3 TRISPECIFIC ANTIBODY
A trispecific antigen binding protein, relating to a trispecific antibody that specifically binds to two tumor antigens of GPRC5D and BCMA and a T cell surface antigen CD3, and a pharmaceutical composition containing the trispecific antibody, a preparation method for the trispecific antibody and a use of the trispecific antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention relates to an antibody that specifically recognizes PVRIG or an antigen-binding fragment thereof, and a preparation method therefor and the use thereof. In addition, the present invention also relates to the therapeutic and diagnostic use of the anti-PVRIG antibody or the antigen-binding fragment thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are modified antibodies, antibody fragments thereof, and antibody-drug conjugates (ADCs) where one or more of the heavy-light chain disulfide bonds are moved to a solvent inaccessible region.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present invention relates to a method for preventing or treating psoriasis in an individual, the method comprises: administering an IL-23p19 antibody to an individual; administering a first dose of the IL-23p19 antibody at weeks 0, 4, and 8, respectively; and administering a second dose of the IL-23p19 antibody every 8-20 weeks thereafter, wherein the first dose is 200 mg, and the second dose is 50 mg-250 mg, preferably 100 mg-200 mg.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
13.
ANTI-CD40L ANTIBODY AND USE THEREOF IN TREATMENT OF HUMAN AUTOIMMUNE DISEASES
An antibody and an antibody fragment that specifically bind to CD40L, and a composition containing the antibody or antibody fragment. In addition, the present invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising same, and the related use.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to an antibody specifically binding to CD79b and a bispecific antibody specifically binding to CD79b and CD3, nucleic acids encoding the anti-CD79b antibody and the anti-CD79b×CD3 bispecific antibody, vectors comprising the nucleic acids, host cells comprising the nucleic acids or the vectors, and pharmaceutical compositions comprising the antibodies or antigen-binding fragments thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Disclosed are compounds of Formula (I' ), antibody drug conjugates (ADCs) of such compounds and pharmaceutical compositions comprising such compounds and/or ADCs of such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer.
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present invention generally relates to Claudin18.2 chimeric antigen receptors. T cells engineered to express Claudin18.2 chimeric antigen receptors (CARs), and uses for treating diseases associated with expression of Claudin18.2.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention discloses use of mazdutide, more particularly, use of a compound of formula (I) in preparing a medicament for reducing a uric acid level in a patient. Formula (I) is shown in the specification. Mazdutide of the present invention has a significant effect of reducing uric acid.
Provided are a pharmaceutical preparation, the use thereof, and a kit comprising same. The pharmaceutical preparation comprises: (1) an anti-VEGFA and anti-VEGFC bispecific binding protein, (2) a buffering agent, (3) a stabilizing agent and (4) a surfactant, wherein the pH of the pharmaceutical preparation is 5.5-7.0. The pharmaceutical preparation shows long-term stability and shows an anti-angiogenesis effect.
The present invention relates to an antibody directed against a vascular endothelial growth factor (VEGF/VEGF-A) and angiopoietin-2 (ANG-2), respectively, a bispecific binding molecule (e.g., an antibody) directed against the vascular endothelial growth factor (VEGF/VEGF-A) and angiopoietin-2 (ANG-2) simultaneously, a preparation method therefor, a pharmaceutical composition comprising the antibody or molecule, and use thereof.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention relates to novel antibodies and antibody fragments specifically binding to ANG-2 and compositions comprising said antibodies or antibody fragments thereof. In addition, the present invention relates to nucleic acids encoding the antibody or antibody fragments thereof and host cells containing the nucleic acids, and their related uses. Furthermore, the present invention relates to the therapeutic and diagnostic use of these antibodies and antibody fragments.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations; gases for medical purposes;
medicines for human purposes; drugs for medical purposes;
dietetic substances adapted for medical use; biological
preparations for veterinary purposes; biocides; medical
dressings; tissues impregnated with pharmaceutical lotions;
dental abrasives; diapers for pets. Conducting technical project studies; scientific research;
research and development of new products for others;
scientific laboratory services; technological research;
chemical research; chemistry services; clinical trials;
biological research; bacteriological research.
The present invention relates to a modified immunoglobulin constant region (Fc) mutant molecule having reduced binding to FcγR or C1q. The molecule can significantly reduce undesired ADCC and/or ADCP and/or CDC effector function in vivo. In addition, the present invention relates to a use of the Fc mutant molecule, a fusion protein comprising the mutant molecule and a use thereof.
Disclosed are an OXM3 storage agent, an OXM3 formulation and a preparation method. The OXM3 storage agent comprises 0.5-5 mg/mL tromethamine, 0.1-100 mg/mL stabilizer, 0.01-5 mg/mL chelating agent and a solvent, wherein: the stabilizer comprises one or more of mannitol, propylene glycol, arginine, arginine hydrochloride, histidine and histidine hydrochloride, the chelating agent comprises edetate disodium, and the solvent comprises water. The OXM3 formulation prepared from the OXM3 storage agent can ensure that the active ingredient OXM3 is stably stored for at least 6 months, preferably for 12 months or more, and more preferably for 18-24 months or more.
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
24.
PREPARATION CONTAINING BISPECIFIC BINDING MOLECULE BINDING TO VEGF AND ANG2 AND USE THEREOF
A preparation containing a bispecific binding molecule binding to VEGF and Ang2 is provided, and a pharmaceutical preparation containing the bispecific binding molecule, a buffer, a stabilizer, and a surfactant is particularly provided. A use of the preparations in treating or preventing diseases is further provided.
The present invention relates to a multispecific fusion protein, and more particularly, relates to a trispecific fusion protein specifically binding to VEGF A, VEGF C and Ang2. The present invention further relates to a polynucleotide encoding the protein, an expression vector and a host cell, a pharmaceutical composition of same, and a method and the use for treating neovascularization-related diseases.
The present invention relates to an isolated anti-CD16A single-domain antibody, and a monospecific antibody molecule or a multispecific antibody molecule comprising the anti-CD16A single-domain antibody as a moiety. The present invention also relates to a nucleic acid encoding the anti-CD16A single-domain antibody, the monospecific antibody molecule, or the multispecific antibody molecules, a host cell comprising the nucleic acid, and a method for preparing the anti-CD16A single-domain antibody, the monospecific antibody molecule, or the multispecific antibody molecule. Furthermore, the present invention relates to use of the anti-CD16A single-domain antibody, the monospecific antibody molecule, or the multispecific antibody molecule for the treatment and/or prevention or diagnosis of acute and chronic infectious diseases (e.g., bacterial or viral infections) or a tumor.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
(1) Pharmaceutical preparations for the treatment of gastrointestinal disorders; gases for medical purposes; medicines for human purposes for the treatment of tumor, ophthalmology diseases, cardiovascular diseases, auto-immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, namely growth and thyroid disorders, reproductive system diseases, namely disorders relating to sexual reproduction and fertility, respiratory system diseases, central and peripheral nervous system diseases, genetic diseases, and for anti-virus; drugs for medical purposes for the treatment of fever; dietetic substances for medical use consisting of vitamins, minerals, amino acids and trace elements; biological preparations for veterinary purposes for the treatment of respiratory infections; biocides; medical dressings; dental abrasives; diapers for pets. (1) Conducting technical project studies in the field of vaccine design; scientific research in the field of medicines for human purposes for the treatment of tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, genetic diseases; research and development of new products for others; scientific laboratory services in the field of immunotherapy; technological research in the field of immunotherapy; chemical research; research and design in the field of chemistry; clinical trials; biological research, namely biomedical research services; bacteriological research.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
Goods & Services
Pharmaceutical preparations for the treatment of gastrointestinal disorders; gases for medical purposes; medicines for human purposes for the treatment of tumor, ophthalmology diseases, cardiovascular diseases, immune diseases, metabolic diseases, blood diseases, diabetes, endocrine system diseases, reproductive system diseases, respiratory system diseases, central and peripheral nervous system diseases, genetic diseases, and for anti-virus; drugs for medical purposes for the treatment of fever; dietetic preparations adapted for medical purposes; biological preparations for veterinary purposes for the treatment of infection; biocides; medical dressings; tissues impregnated with antibacterial preparations; dental abrasives; diapers for pet Scientific research featuring technical project studies in the field of vaccine design; scientific research in the field of pharmaceuticals; research and development of new products for others; scientific laboratory services; technological research in the field of immunotherapy; chemical research; research and development services in the field of chemistry; scientific research in the nature of conducting clinical trials for others; biological research; bacteriological research
The present invention relates to a novel interleukin-21 (IL-21) mutant protein and use thereof. In particular, the present invention relates to an IL-21 mutant protein that has improved properties, such as a reduced binding property to an IL-21 receptor and improved druggability, compared to wild-type IL-21. The present invention also provides a fusion comprising the IL-21 mutant protein, a nucleic acid encoding the IL-21 mutant protein or the fusion, and a vector and a host cell comprising the nucleic acid. The present invention further provides a method for preparing the IL-21 mutant protein or the fusion, a pharmaceutical composition comprising the same, and therapeutic use.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
30.
PROTEIN CONTAINING HETERODIMER ANTIBODY FC, AND PREPARATION METHOD THEREFOR
The present invention relates to novel proteins containing heterodimeric antibody Fc such as bispecific antibodies, and novel methods for preparing such proteins.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
The present invention relates to an anti-TNFR2 antibody, a preparation method therefor, a composition thereof, and use thereof. The present invention also provides a method for treating a TNFR2-associated disease and/or disorder, such as cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
The present invention relates to a multispecific antibody, such as a bispecific antibody, comprising a mutated amino acid pair capable of promoting homologous pairing of a heavy chain and a light chain of the multispecific antibody.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
Provided are an antibody or an antigen-binding fragment for a coronavirus S protein, a nucleic acid encoding the antibody or the antigen-binding fragment, a host cell comprising the nucleic acid, and a method for preparing the antibody or the antigen-binding fragment. Also provided is a use of the antibody or the antigen-binding fragment in prevention, treatment, and/or diagnosis of coronavirus.
The present invention belongs to the field of medicine, and specifically relates to a treatment method using mazdutide. The present invention provides a method for preventing or treating overweight and obesity, and a method for improving body weight in patients in need, the method comprising administering, to a patient in need, a prophylactically or therapeutically effective amount of a target compound in a dosage regimen comprising at least three dosing cycles. The present invention also provides a target compound, which is used for preventing or treating overweight or obesity in patients in need, wherein a prophylactically or therapeutically effective amount of the target compound is administered in at least three dosing cycles to a patient in need. The mazdutide dosage regimen provided has a remarkable weight reduction effect, noticeable weight reduction can be achieved with relatively low dosage in a relatively short amount of time, and blood pressure, blood lipid, and serum uric acid levels of a subject can simultaneously be improved.
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
The present invention relates to novel antibodies or antigen-binding fragments thereof that specifically bind to CD73 and compositions comprising the antibodies or antigen-binding fragments thereof. The present invention also relates to a nucleic acid encoding the antibody or antigen-binding fragment thereof of the present invention, a vector comprising the polynucleotide, a host cell comprising the nucleic acid or the vector, an immunoconjugate and pharmaceutical composition comprising the antibody or antigen-binding fragment thereof. Furthermore, the present invention relates to the uses of these antibodies or antigen-binding fragments thereof in the immunotherapy, prevention and/or diagnosis of diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
The present invention belongs to the field of medicinal chemistry, and relates to a novel KRAS G12C protein inhibitor, a preparation method and use thereof. In particular, the present invention provides a compound of formula I, which can be used as a high-efficiency KRAS G12C protein inhibitor and has various pharmacological activities against tumors, proliferative diseases, inflammation, autoimmune diseases, etc.
The present invention belongs to the field of medicinal chemistry, and relates to a novel KRAS G12C protein inhibitor, a preparation method and use thereof. In particular, the present invention provides a compound of formula I, which can be used as a high-efficiency KRAS G12C protein inhibitor and has various pharmacological activities against tumors, proliferative diseases, inflammation, autoimmune diseases, etc.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Provided are an antibody having an improved affinity for specifically binding to BCMA, an antibody comprising a P329G mutation, and a conjugate, a fusion, a bispecific antibody or a pharmaceutical composition comprising the antibody. In addition, further provided are a nucleic acid encoding the antibody, a host cell comprising the nucleic acid, and a method for preparing the antibody. The present invention also relates to the therapeutic and diagnostic use of the antibody binding to BCMA.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a formulation comprising an anti-IL-23p19 antibody, and in particular to a pharmaceutical formulation comprising an anti-IL-23p19 antibody, a buffer, a stabilizer and a surfactant. Furthermore, the present invention further relates to therapeutic or prophylactic use of these formulations.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
40.
PHARMACEUTICAL COMBINATION COMPRISING ANTI-PD-1 ANTIBODY AND ANTI-VEGF-A ANTIBODY AND METHOD FOR USING SAME
Provided is a pharmaceutical combination comprising an anti-PD-1 antibody and one or more chemotherapeutic agents, wherein the pharmaceutical combination can further contain an anti-VEGF-A antibody. Also provided are the use and a method of using the pharmaceutical combination in the prevention or treatment of cancers.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Disclosed are a new interleukin-2 (IL-2) mutant protein and the use thereof. Compared with wild-type IL-2, the IL-2 mutant protein has improved properties, such as an improved IL-2 receptor binding property and improved druggability. Also provided are a fusion protein, dimer and immunoconjugate comprising the IL-2 mutant protein, nucleic acids encoding the IL-2 mutant protein, the dimer and the immunoconjugate, and a vector and host cell comprising the nucleic acid. Further provided are methods for preparing the IL-2 mutant protein, the fusion protein, the dimer and the immunoconjugate, a pharmaceutical composition containing same, and the therapeutic use thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A pharmaceutical composition containing an anti-PD-1 antibody and a chemotherapy agent, as well as a use thereof and a method for using same for preventing or treating tumors, particularly esophageal cancer.
The present invention relates to formulations comprising an anti-TIGIT antibody, and in particular to a pharmaceutical formulation comprising an anti-TIGIT antibody, a buffer, a stabilizer and a surfactant. Furthermore, the present invention further relates to therapeutic or prophylactic use of these formulations.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
44.
USE OF FUSION PROTEIN IN TREATMENT OF AGE-RELATED MACULAR DEGENERATION
The present invention relates to use of a fusion protein in the treatment of age-related macular degeneration. In particular, the present invention relates to use of a bispecific fusion protein inhibiting the activation of a complement pathway and a vascular endothelial growth factor (VEGF) pathway for the treatment of age-related macular degeneration. The present invention also relates to a pharmaceutical composition comprising the fusion protein and a method for treating age-related macular degeneration using the fusion protein.
A single-domain antibody polypeptide specifically binding to VEGF C and a construct thereof, an anti-VEGF C/VEGF A bispecific binding protein, polynucleotides encoding the polypeptide and protein, an expression vector, a host cell, a pharmaceutical composition thereof, and a method and use for treating diseases related to neovascularization.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
A single-domain antibody polypeptide specifically binding to VEGF C and a construct thereof, an anti-VEGF C/VEGF A bispecific binding protein, polynucleotides encoding the polypeptide and protein, an expression vector, a host cell, a pharmaceutical composition thereof, and a method and use for treating diseases related to neovascularization.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are an antibody that specifically binds to CD79b, a bispecific antibody that specifically binds to CD79b and CD3, nucleic acids encoding the anti-CD79b antibody and the anti-CD79b×CD3 bispecific antibody, vectors comprising the nucleic acids, host cells comprising the nucleic acids or vectors, and pharmaceutical compositions containing the antibodies or antigen binding fragments thereof.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
48.
ANTI-CD79B×CD3 BISPECIFIC ANTIBODY AND USE THEREOF
Provided are an antibody that specifically binds to CD79b, a bispecific antibody that specifically binds to CD79b and CD3, nucleic acids encoding the anti-CD79b antibody and the anti-CD79b×CD3 bispecific antibody, vectors comprising the nucleic acids, host cells comprising the nucleic acids or vectors, and pharmaceutical compositions containing the antibodies or antigen binding fragments thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Disclosed is the use of mazdutide. Specifically disclosed is the use of a compound as represented by formula (I) in the preparation of a drug for reducing the uric acid level of a patient. Mazdutide has a significant uric acid reduction effect.
Disclosed is the use of mazdutide. Specifically disclosed is the use of a compound as represented by formula (I) in the preparation of a drug for reducing the uric acid level of a patient. Mazdutide has a significant uric acid reduction effect.
Provided are a novel antibody and antibody fragment that specifically bind claudin (CLDN) 18.2 and a conjugate containing the antibody or the antibody fragment. In addition, provided are a nucleic acid encoding the antibody or the antibody fragment thereof and a host cell comprising same, and related use. The antibody or an antigen binding fragment or the conjugate can be used for diagnosing cancer and/or determining whether cancer cells express CLDN18.2.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are an antibody against a vascular endothelial growth factor (VEGF/VEGF-A) and angiopoietin-2 (ANG-2) respectively, a bispecific binding molecule (for example, an antibody) simultaneously against VEGF/VEGF-A and ANG-2, a preparation method therefor, and a pharmaceutical composition containing the antibody or molecule and an application thereof.
Provided are an antibody against a vascular endothelial growth factor (VEGF/VEGF-A) and angiopoietin-2 (ANG-2) respectively, a bispecific binding molecule (for example, an antibody) simultaneously against VEGF/VEGF-A and ANG-2, a preparation method therefor, and a pharmaceutical composition containing the antibody or molecule and an application thereof.
Provided is a drug combination of a quinoline derivative and a PD-1 monoclonal antibody, which contains a tyrosine kinase inhibitor and an immune checkpoint inhibitor, wherein the tyrosine kinase inhibitor is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The drug combination has good activity against endometrial tumors.
An anti-Siglec-15 antibody and the use thereof. The antibody or an antigen-binding fragment thereof comprises six complementary determining regions (CDRs). The antibody can bind to the Siglec-15 protein with high affinity and effectively relieve the inhibition of the Siglec-15 protein on the proliferation and activation of T cells, and can relieve the inhibitory effect of the Siglec-15 protein on tumor immune response, enhance the tumor immune response, and inhibit tumor growth in a mouse in-vivo tumor model, thereby showing an effective anti-tumor potency.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to a modified immunoglobulin constant region (Fc) mutant molecule having reduced binding to Fc?R or C1q. The molecule can significantly reduce undesired ADCC and/or ADCP and/or CDC effector function in vivo. In addition, the present invention relates to a use of the Fc mutant molecule, a fusion protein comprising the mutant molecule and a use thereof.
The present invention relates to a modified immunoglobulin constant region (Fc) mutant molecule having reduced binding to FcγR or C1q. The molecule can significantly reduce undesired ADCC and/or ADCP and/or CDC effector function in vivo. In addition, the present invention relates to a use of the Fc mutant molecule, a fusion protein comprising the mutant molecule and a use thereof.
Provided are an OXM3 storage agent, an OXM3 preparation, and a preparation method. The OXM3 storage agent comprises 0.5-5 mg/ml tromethamine, 0.1-100 mg/ml of a stabilizer, 0.01-5 mg/ml of a chelating agent, and a solvent. The stabilizer comprises one or more of: mannitol, propylene glycol, arginine, arginine hydrochloride, histidine, and histidine hydrochloride; the chelating agent comprises disodium edetate; and the solvent comprises water. The OXM3 preparation prepared from the OXM3 storage agent can ensure that the active ingredient OXM3 is stably stored for at least six months, preferably for 12 months or more, and more preferably for 18-24 months or more.
Provided are an OXM3 storage agent, an OXM3 preparation, and a preparation method. The OXM3 storage agent comprises 0.5-5 mg/ml tromethamine, 0.1-100 mg/ml of a stabilizer, 0.01-5 mg/ml of a chelating agent, and a solvent. The stabilizer comprises one or more of: mannitol, propylene glycol, arginine, arginine hydrochloride, histidine, and histidine hydrochloride; the chelating agent comprises disodium edetate; and the solvent comprises water. The OXM3 preparation prepared from the OXM3 storage agent can ensure that the active ingredient OXM3 is stably stored for at least six months, preferably for 12 months or more, and more preferably for 18-24 months or more.
The present invention relates to use of an anti-PCSK9 antibody and/or antibody fragment thereof and a pharmaceutical preparation comprising the same in a method for preventing or treating a cholesterol-related disease. Furthermore, the present invention relates to an anti-PCSK9 antibody or a liquid preparation thereof for preventing or treating the above disease.
The present invention relates to formulations comprising an anti-PD-1/HER2 bispecific antibody, and in particular to a pharmaceutical formulation comprising the anti-PD-1/HER2 bispecific antibody, a buffer, a stabilizer and a surfactant. Furthermore, the present invention also relates to therapeutic or prophylactic use of these formulations.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention relates to a trispecific antigen binding protein, and more specifically to a trispecific antibody specifically binding to two tumor antigens of GPRC5D and BCMA and T cell surface antigen CD3, and a pharmaceutical composition comprising same, a preparation method and the use.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present invention relates to a trispecific antigen binding protein, and more specifically to a trispecific antibody specifically binding to two tumor antigens of GPRC5D and BCMA and T cell surface antigen CD3, and a pharmaceutical composition comprising same, a preparation method and the use.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
64.
Miniaturized antibody of anti-glucocorticoid-induced tumor necrosis factor receptor (GITR), and polymer and use thereof
An antibody that specifically binds to a glucocorticoid-induced tumor necrosis factor receptor (GITR), an antibody fragment and a polymer thereof, and a conjugate and a fusion comprising the antibody or the antibody fragment are provided in the present invention. A nucleic acid encoding the antibody, the antibody fragment, the polymer, the conjugate and the fusion, a vector, and a host cell expressing the nucleic acid are also provided in the present invention. In addition, a composition comprising the antibody and the antibody fragment thereof, the polymer, the conjugate or the fusion, and use thereof in therapy and diagnosis are also provided in the present invention.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention discloses a cell culture method based on high-density and continuous inoculation and use thereof. The method comprises the following steps: (1) providing a cell culture, and performing resuscitation, shake flask amplification culture and rocking reaction bag amplification culture on the cell culture; (2) transferring the resuscitated and amplified cells into a last-stage cell amplification tank for continuous amplification culture; (3) inoculating the cells in the last-stage cell amplification tank into a culture fermentation tank in a high-density and continuous inoculation mode for fermentation culture; and (4) harvesting a target product. The cell culture method based on high-density and continuous inoculation provided herein can reduce the average cell passage time of each batch and improve the production efficiency of cells and expression products thereof.
Provided are a TNFR2 antibody, a preparation method therefor, a composition, and the use thereof. Further provided are a method for treating TNFR2-related diseases and/or disorders, such as cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Provided are a TNFR2 antibody, a preparation method therefor, a composition, and the use thereof. Further provided are a method for treating TNFR2-related diseases and/or disorders, such as cancer.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to formulations comprising an anti-LAG-3 antibody, and in particular to pharmaceutical formulations comprising an antibody specifically binding to LAG-3 molecules, a buffer, a stabilizer and a surfactant. Furthermore, the present invention also relates to therapeutic or prophylactic use of these formulations.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to formulations comprising an anti-CD47/PD-L1 bispecific antibody, and in particular to pharmaceutical formulations comprising an anti-CD47/PD-L1 bispecific antibody, a buffer, a stabilizer and a surfactant. Furthermore, the present invention also relates to therapeutic or prophylactic use of these formulations.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 9/00 - Medicinal preparations characterised by special physical form
70.
SINGLE-DOMAIN ANTIBODY AGAINST CD16A AND USE THEREOF
The present invention relates to an isolated anti-CD16A single-domain antibody, and a monospecific antibody molecule or a multispecific antibody molecule comprising the anti-CD16A single-domain antibody as a moiety. The present invention also relates to a nucleic acid encoding the anti-CD16A single-domain antibody, and the monospecific antibody molecule or the multispecific antibody molecule; a host cell comprising the nucleic acid; and a method for preparing the anti-CD16A single-domain antibody, and the monospecific antibody molecule or the multispecific antibody molecule. Furthermore, the present invention relates to the use of the anti-CD16A single-domain antibody, and the monospecific antibody molecule or the multispecific antibody molecule in the treatment and/or prevention or diagnosis of acute and chronic infectious diseases (e.g. bacterial infection or viral infection) and tumors.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
71.
SINGLE-DOMAIN ANTIBODY AGAINST CD16A AND USE THEREOF
The present invention relates to an isolated anti-CD16A single-domain antibody, and a monospecific antibody molecule or a multispecific antibody molecule comprising the anti-CD16A single-domain antibody as a moiety. The present invention also relates to a nucleic acid encoding the anti-CD16A single-domain antibody, and the monospecific antibody molecule or the multispecific antibody molecule; a host cell comprising the nucleic acid; and a method for preparing the anti-CD16A single-domain antibody, and the monospecific antibody molecule or the multispecific antibody molecule. Furthermore, the present invention relates to the use of the anti-CD16A single-domain antibody, and the monospecific antibody molecule or the multispecific antibody molecule in the treatment and/or prevention or diagnosis of acute and chronic infectious diseases (e.g. bacterial infection or viral infection) and tumors.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are a novel interleukin-21 (IL-21) mutant protein and the use thereof. Specifically, compared with the wild-type IL-21, the IL-21 mutant protein has improved properties, for example, a reduced IL-21 receptor binding property and improved druggability. Also provided are a fusion containing the IL-21 mutant protein, a nucleic acid encoding the IL-21 mutant protein and the fusion, and a vector and a host cell containing the nucleic acid. Further provided are a method for preparing the IL-21 mutant protein and the fusion, a pharmaceutical composition containing same, and the therapeutic use thereof.
Provided are a biomarker of a PD-L1 protein and/or related genes based on MHC-II and a kit comprising the biomarker, as well as use of the expression of the biomarker in the preparation of a kit for predicting and identifying lung cancer patients likely to respond to therapy or use of a kit comprising the biomarker in the method for predicting and identifying lung cancer patients likely to respond to therapy. In addition, further provided is a method for predicting and identifying lung cancer patients likely to respond to PD-1 antagonist therapy or combination therapy of PD-1 antagonist and chemotherapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
Related are a novel antibody specifically binding with B7-H3, an antigen-binding fragment of the antibody, and a composition comprising the antibody or the antigen-binding fragment thereof. Related are nucleic acids encoding the antibody or the antigen-binding fragment thereof, a host cell comprising the nucleic acids, and relevant uses. In addition, related are therapeutic and diagnostic uses of the antibody and the antigen-binding fragment thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Provided are a novel bispecific antibody that specifically binds to BCMA and CD3, a nucleic acid encoding the anti-BCMA×CD3 bispecific antibody, a vector containing the nucleic acid, a host cell containing the nucleic acid or vector, and a pharmaceutical composition containing the antibody or an antigen-binding fragment thereof. In addition, further provided is the use of the anti-BCMA×CD3 bispecific antibody and the pharmaceutical composition in immunotherapy, and the prevention and/or diagnosis of diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are a Claudin18.2 chimeric antigen receptor (CAR), a T cell that is engineered to express a Claudin18.2 CAR, and a use of the CAR and T cell for treating diseases related to Claudin18.2 expression.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Provided are a novel interleukin-21 (IL-21) mutant protein and the use thereof. Specifically, compared with the wild-type IL-21, the IL-21 mutant protein has improved properties, for example, a reduced IL-21 receptor binding property and improved druggability. Also provided are a fusion containing the IL-21 mutant protein, a nucleic acid encoding the IL-21 mutant protein and the fusion, and a vector and a host cell containing the nucleic acid. Further provided are a method for preparing the IL-21 mutant protein and the fusion, a pharmaceutical composition containing same, and the therapeutic use thereof.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
79.
PREPARATION COMPRISING ANTI-TIGIT/PD-1 BISPECIFIC ANTIBODY, METHOD FOR PREPARING SAME, AND USE THEREOF
The present invention relates to a preparation comprising an anti-TIGIT/PD-1 bispecific antibody, and in particular to a pharmaceutical preparation comprising an anti-TIGIT/PD-1 bispecific antibody, a buffering agent, a stabilizing agent, and a surfactant. In addition, the present invention further relates to a use of these preparations in treating or preventing diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A new fusion protein including a PD-L1 antibody and a TGFβ receptor, a nucleic acid encoding the fusion protein or a fragment thereof, a host cell comprising same, and the relevant use. In addition, the present invention also relates to the therapeutic use of said fusion proteins or a fragment thereof.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention relates to a formulation comprising an anti-CD47 antibody, and in particular to a pharmaceutical formulation comprising an antibody, a buffer, a stabilizer and a surfactant. Furthermore, the present invention also relates to therapeutic or prophylactic use of those formulations.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
Provided is a fusion protein applicable in a tumor treatment and a hematopoietic stem cell transplantation. Specifically, provided is a fusion protein having excellent pharmaceutical properties and stability and formed by a truncated FLT3 ligand and an antibody Fc region. Also provided are nucleic acids encoding the fusion protein, a vector comprising the nucleic acids, a host cell, and a method for producing the fusion protein. Also provided are a pharmaceutical composition and a pharmaceutical concomitant comprising the fusion protein, and medicinal uses thereof.
The present invention relates to a novel single-domain antibody and a fragment thereof that specifically bind to PD-L1 and a composition comprising the antibody or the fragment thereof. In addition, the present invention relates to a nucleic acid encoding the antibody or the fragment thereof, a host cell comprising the nucleic acid, and related uses. Furthermore, the present invention relates to therapeutic and diagnostic uses of the antibody and the fragment thereof. In particular, the present invention relates to combination therapies of these antibodies and the fragments thereof with other therapies, such as therapeutic modalities or therapeutic agents.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
84.
NOVEL BISPECIFIC ANTIBODY MOLECULE AND BISPECIFIC ANTIBODY SIMULTANEOUSLY BINDING TO PD-L1 AND LAG-3
The present invention provides a novel, artificially designed antibody molecule comprising: a polypeptide chain of formula (I):
The present invention provides a novel, artificially designed antibody molecule comprising: a polypeptide chain of formula (I):
VH-CH1-Fc-X-VHH; and
a polypeptide chain of formula (II):
The present invention provides a novel, artificially designed antibody molecule comprising: a polypeptide chain of formula (I):
VH-CH1-Fc-X-VHH; and
a polypeptide chain of formula (II):
VL-CL;
wherein:
the VH represents a heavy chain variable region;
the CH represents a heavy chain constant region;
the Fc comprises CH2, CH3, and optionally CH4;
the CH1, the CH2, the CH3 and the CH4 represent domains 1, 2, 3 and 4, respectively, of the heavy chain constant region;
the X may be absent, or represents a linker such as a flexible linker when present;
the VHH represents a single-domain antigen-binding site such as a single-domain antibody;
the VL represents a light chain variable region;
the CL represents a light chain constant region;
optionally, a hinge region is present between the CH1 and the Fc.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A novel antibody and antibody fragment specifically biding to CD3, and composition comprising the antibody or antibody fragment. Nucleic acids encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acids, relevant uses, and therapeutic and diagnostic uses of the antibody and of the antibody fragment.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
The present invention relates to a novel bispecific antibody specifically binding to Claudin18.2 and CD3 and an antibody fragment, and a composition containing the bispecific antibody or the antibody fragment. In addition, the present invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof and a host cell comprising the nucleic acid, and the related use. Furthermore, the present invention relates to the therapeutic and diagnostic use of the bispecific antibody and the antibody fragment.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are an antibody or an antigen-binding fragment for a coronavirus S protein, a nucleic acid encoding the antibody or the antigen-binding fragment, a host cell comprising the nucleic acid, and a method for preparing the antibody or the antigen-binding fragment. Also provided is a use of the antibody or the antigen-binding fragment in prevention, treatment, and/or diagnosis of coronavirus.
A lung cancer biomarker, a detection method, and an application thereof. The lung cancer biomarker includes the following genes: CASP8 and/or ADAP2, or further includes one or more of ITGB2, MPP1, PI3K3AP1, GBGT1, RAB27A, CD180, RLN3, CD84, DRAM1, HLA-DMB, OTULIN, HELZ, VDR, HLA-DPA1, MX2, FUCA1, MKRN1, and NEK6, said genes being the genes most significantly associated with immune combination therapy PFS in the tumour microenvironment. Use of the lung cancer biomarker can play a good role in predicting or evaluating the prognostic efficacy of treatment with PD1/PDL1 pathway immune checkpoint inhibitors combined with chemotherapy drugs.
The present invention relates to a preparation comprising an anti-PCSK9 antibody and use thereof, and in particular to a pharmaceutical preparation comprising an antibody and/or an antibody fragment specifically binding to proprotein convertase subtilisin/kexin type 9 (PCSK9), a buffer, a viscosity inhibitor, and a surfactant. The present invention also relates to an anti-PCSK9 antibody. Furthermore, the present invention relates to therapeutic and diagnostic use of the preparation or the antibody.
The present invention provides an artificially designed antibody molecule comprising four polypeptide chains, where each of the first polypeptide chain and the third polypeptide chain comprises an immunoglobulin light chain, and each of the second polypeptide chain and the fourth polypeptide chain comprises, from the N-terminus to the C-terminus, an immunoglobulin heavy chain variable region, an immunoglobulin CH1 domain, a VHH, an immunoglobulin CH2 domain, an immunoglobulin CH3 domain, and optionally an immunoglobulin CH4 domain.
The present invention also provides a polynucleotide encoding the antibody molecule, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, an immunoconjugate and a pharmaceutical composition comprising the antibody molecule, and use of the antibody molecule in the immunotherapy, prevention and/or diagnosis of diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
91.
PD-L1/LAG-3 BISPECIFIC ANTIBODY PREPARATION, AND PREPARATION METHOD THEREFOR AND USE THEREOF
Provided are a pharmaceutical preparation containing a PD-L1/LAG-3 double antibody, a buffer, a stabilizer, a surfactant and a chelating agent, and the corresponding therapeutic or preventive use thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
92.
SERIES OF BIOMARKERS OF CONSENSUS SEQUENCES IN CDR3 SEQUENCE OF TCR-β CHAIN AND APPLICATION THEREOF
A series of biomarkers of consensus sequences in a CDR3 sequence of a TCR-β chain and an application thereof. Provided is a set of biomarkers, characterized in that the biomarkers are consensus sequences in the CDR3 sequence of a T cell receptor (TCR) β chain. Preferably, the amino acid sequence of the biomarkers comprises RGG. The biomarkers provided may be used to predict the clinical response effect of PD1/PDL1 pathway immune checkpoint inhibitors to tumors, especially Hodgkin's lymphoma. High-throughput sequencing and statistical analysis are performed on the CDR3 sequence of the TCR-β chain of Hodgkin's lymphoma patients who are given the PD1/PDL1 pathway immune checkpoint inhibitors, and a dominant sequence is determined. By means of the enrichment analysis of the dominant sequence, it is helpful to monitor and predict the response and irAE of the patient after checkpoint immunotherapy.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Provided is a nucleotide combination and a use thereof. The nucleotide combination comprises the following genes: CD74, CTSZ, ACP5, MS4A6A, CD83, NPC2, GPNMB, C1QB, HLA-DPA1, and HLA-DMB, or mutations of said genes; and/or a gene such as LAP3, IFNGR1, TBXAS1, SPI1, SNX10 or mutations of said genes. The genes are genes specifically expressed by a macrophage in a tumor microenvironment. Using the nucleotide combination allows for effective disease prediction or prognostic diagnosis, and especially provides a good predictive effect in combined treatment with a PD1/PDL1 pathway immune checkpoint inhibitor and a chemotherapy drug.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
94.
COMBINATION OF ANTI-CD47 ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF AND DNA METHYLTRANSFERASE INHIBITOR AND USE THEREOF
Provided are a pharmaceutical combination of an anti-CD47 antibody or an antigen binding fragment thereof and a DNA methyltransferase inhibitor, a pharmaceutical composition or a kit comprising the pharmaceutical combination, and a method for preventing and/or treating tumors and/or cancers by using the pharmaceutical combination, the pharmaceutical composition or the kit. The anti-CD47 antibody or the antigen binding fragment thereof in combination with a DNA methyltransferase inhibitor has excellent anti-tumor pharmaceutical effects, and especially exerts synergistic anti-tumor effects on AML and MDS indications.
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Novel antibodies and antibody fragments specifically binding to ANG-2, and a composition containing the antibodies or antibody fragments. A nucleic acid encoding the antibodies or the antibody fragments thereof, and related use are involved. In addition, therapeutic and diagnostic use of these antibodies and antibody fragments is involved.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a novel antibody or an antigen-binding fragment thereof which specifically bind to CD73, and a composition containing the antibody or the antigen-binding fragment thereof. The present invention further relates to a nucleic acid encoding the antibody or the antigen-binding fragment thereof, a vector containing a polynucleotide, a host cell containing the nucleic acid or the vector, and an immunoconjugate and a pharmaceutical composition containing the antibody or the antigen-binding fragment thereof. In addition, the present invention further relates to an application of the antibody or the antigen-binding fragment thereof in the immunotherapy, prevention, and/or diagnosis of diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Novel antibodies and antibody fragments specifically binding to ANG-2, and a composition containing the antibodies or antibody fragments. A nucleic acid encoding the antibodies or the antibody fragments thereof, and related use are involved. In addition, therapeutic and diagnostic use of these antibodies and antibody fragments is involved.
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided are a novel antibody specifically binding Claudin18.2 and an antibody fragment as well as a composition containing the antibody or the antibody fragment. Further provided are a nucleic acid encoding the antibody or the antibody fragment thereof and a host cell comprising the same as well as related uses. Further provided are therapeutic and diagnostic uses of the antibody and antibody fragment.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The invention relates to a novel antibody and an antibody fragment thereof that specifically bind to ALG-3 and a composition comprising the antibody or the antibody fragment. In addition, the invention relates to a nucleic acid encoding the antibody or the antibody fragment thereof, a host cell comprising the nucleic acid, and related use. Furthermore, the invention relates to therapeutic and diagnostic use of the antibody and the antibody fragment. In particular, the invention relates to combination therapy of the antibodies and the antibody fragments described herein with other therapeutic agents, such as anti-PD-1 or anti-PD-L1 antibodies.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
